Neurocrine Biosciences, Inc.
NBIX
$118.78
$1.911.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.90M | 103.10M | 129.80M | 65.00M | 43.40M |
| Total Depreciation and Amortization | 7.60M | 7.10M | 6.50M | 7.30M | 6.20M |
| Total Amortization of Deferred Charges | -- | -- | -138.40M | 49.70M | 88.70M |
| Total Other Non-Cash Items | 73.00M | 38.00M | 155.70M | 28.90M | 23.60M |
| Change in Net Operating Assets | -23.70M | 94.30M | 4.40M | -86.30M | -31.60M |
| Cash from Operations | 64.80M | 242.50M | 158.00M | 64.60M | 130.30M |
| Capital Expenditure | -10.70M | -7.30M | -8.10M | -11.60M | -11.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.90M | -61.00M | 32.80M | -16.60M | -43.80M |
| Cash from Investing | 14.20M | -68.30M | 24.70M | -28.20M | -55.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | -308.80M | -- |
| Issuance of Common Stock | 32.10M | 10.00M | 26.40M | 15.80M | 69.90M |
| Repurchase of Common Stock | -150.00M | -300.00M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -117.90M | -290.00M | 26.40M | -293.00M | 69.90M |
| Foreign Exchange rate Adjustments | -- | -300.00K | 300.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -38.90M | -116.10M | 209.40M | -256.60M | 145.20M |